Compare KKR & Co Inc (KKR) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Novavax Inc — how do they compare? KKR & Co Inc trades at $90.95 (market cap $80.39B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: KKR & Co Inc is far larger — about 44.2× Novavax Inc's market cap, and KKR & Co Inc pays a 0.87% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Novavax Inc for 59 Days on average.
| KKR | NVAX | |
|---|---|---|
Market Cap | $80.39B | $1.82B |
Volume | 6,517,705 | 6,198,505 |
Sector | Financials | Health |
52-Week High | $142.75 | $12.56 |
52-Week Low | $83.88 | $6.22 |
Typical Hold Time | 67 Days | 59 Days |
Enterprise Value | $2.95B | $1.39B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $89.56, down 0.12% with bearish technical signals despite strong analyst support. The company reported mixed quarterly results with Q2 2026 EPS beating expectations at $1.63 versus $1.43 estimate, while Q4 2025 missed. Recent business activity includes joint ventures with Thomson Reuters and Realty Income, plus multiple asset sales in Asia. Financial trends show revenue stabilizing around $19-21B with net margins improving to 14.96% projected for 2026.
The investment case balances strong Wall Street bullishness (88.9% buy ratings, $123.30 consensus target) against technical weakness and volatile cash flows. Key opportunities include continued earnings beats and strategic partnerships, while risks involve significant debt levels and market-sensitive investment returns. The stock presents a value gap if fundamentals can overcome current technical pressure.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
